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ABSTRACT
Background. Neoadjuvant chemoradiation therapy
(CRT) has been widely implemented in the treatment of
rectal cancer patients, but optimal timing of surgery after
neoadjuvant therapy is unclear. The purpose of this study
was to evaluate the effects of prolonged intervals between
long-course CRT and surgery in rectal cancer patients.
Methods. Data on all rectal cancer patients diagnosed
between 2006 and 2011 were retrieved from the popula-
tion-based Netherlands Cancer Registry; the main outcome
parameters were pathologic complete response (pCR) and
overall survival (OS). Outcomes were reported separately
for patients with early tumors (ETs; N = 217) and locally
advanced rectal cancer (LARC; N = 1073). Patients were
divided into 2-week interval groups according to treatment
interval, ranging from 5–6 to 13–14 weeks. Kaplan–Meier
curves, and logistic regression and Cox regression models
were used for data analysis.
Results. No significant difference in pCR rate was
observed for ET patients according to treatment interval.
Compared with a treatment interval of 7–8 weeks, pCR
rates in LARC patients were higher after 9–10 weeks
(18.4 %; odds ratio [OR] 1.56, 95 % CI 1.03–2.37) and 11–
12 weeks of treatment interval (20.8 %; OR 1.94, 95 % CI
1.15–3.26). Treatment interval did not influence OS in ET
or LARC patients.
Conclusions. Treatment intervals of 9–12 weeks between
surgery and CRT seem to improve the chances of pCR in
LARC patients, without an effect on OS. The length of
treatment interval did not affect outcomes in patients with
ET. The ongoing search for minimally invasive surgery
drives the need for exploration of factors that improve
pathologic response.
In The Netherlands, rectal cancer is diagnosed in
approximately 4500 patients annually.1 Total mesorectal
excision (TME) is the gold standard in rectal cancer sur-
gery and comprises resection of the rectal tumor together
with the fatty tissue surrounding the rectum.2 Neoadjuvant
treatment is used to improve outcome in case lymph node
involvement is suspected or when the tumor extends to the
mesorectal fascia on magnetic resonance imaging (MRI).3
For locally advanced rectal cancer (LARC), therapy
consists of chemoradiation therapy (CRT) followed by
TME or even beyond TME surgery.4 CRT consists of long-
course radiotherapy of 45–50 Gy (in fractions of 1.8–
2 Gy), with concurrent 5-fluorouracil. Treatment for early
tumors (ETs) without suspicion of lymph node involve-
ment (cT1–3N0) consists of TME surgery only; however,
in a search for organ-sparing treatment modalities, CRT
has also recently been applied to ET patients followed by
local transanal excision.5–11 The wait-and-see approach has
recently been introduced for both LARC and ET
patients.12–14
Although neoadjuvant CRT has been widely imple-
mented in the treatment of rectal cancer patients, the
optimal timing of surgery after neoadjuvant therapy is as yet
unclear.15 Surgery was previously performed 6–8 weeks
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after completion of CRT;16,17 however, recent studies
suggest a time-related response of the tumor to CRT. There
is growing evidence that extending the treatment interval
might increase the proportion of patients with a complete
pathologic response (pCR).18 It has also been suggested that
a prolongation of the treatment interval might improve
overall survival (OS).18,19 A meta-analysis on this topic did
not show better OS in patients with longer treatment
intervals, but the amount of evidence was scarce and the
authors suggested further validation of the results.18
The currently available literature concerning the treat-
ment interval between CRT and surgery does not
differentiate between ET and LARC patients, despite the
fact that there are substantial differences in oncological
outcomes. This nationwide study aimed to evaluate the
effects of prolonged treatment intervals on pCR and OS in
ET and LARC patients separately.
METHODS
Data on all rectal cancer patients diagnosed between
2006 and 2011 in The Netherlands were retrieved from the
population-based Netherlands Cancer Registry (NCR). The
main source of notification of the NCR is the automated
pathological archive (PALGA). Data were extracted from
the medical records by trained registrars. Tumors are
staged according to the TNM classification (5th edition)
and classified according to the International Classification
of Diseases for Oncology (ICD-O).
According to Dutch guidelines, all patients are staged
using MRI.17 CRT is administered in patients with cT4 or
cT3 and distance to the mesorectal fascia B1 mm, or cN2
and/or positive extramesorectal lymph nodes. All patients
who were treated with neoadjuvant CRT followed by any
kind of surgery were selected (n = 3042). Patients who
were diagnosed with a tumor other than adenocarcinoma
not otherwise specified (AC), mucinous adenocarcinoma,
and signet ring cell adenocarcinoma were excluded
(n = 30). Patients with metastatic disease (n = 249) or a
treatment interval between CRT and surgery of\5 weeks
or [15 weeks (n = 101) were also excluded since these
were considered outliers (electronic supplementary Fig. 1).
Missing data could not be retrieved retrospectively and
patients for whom data concerning the time interval
between CRT and surgery were unavailable were also
excluded from the analysis (n = 1186). ETs were defined
as a stage cT1-3N0 tumor (n = 217), and LARC was
defined as a stage cT3Nx, cT3N1, cT4 and/or cN2 tumor
(n = 1073). Patients with a cTx, cT1N1, or cT2N1 tumor
(n = 186) did not meet the criteria of either of the groups
and were not further analyzed.
pCR was defined as ypT0N0, and good pathologic
response was defined as ypT0–T1N0. Registration of the
circumferential resection margin (CRM) of the variables,
and distance to anus in the cancer registry, was available
from 2008. CRM was considered positive in case of a
tumor-free resection margin B1 mm. The treatment inter-
val was calculated from the end of CRT until the date of
surgery, and follow-up data on vital status were retrieved
by linkage to the nationwide municipal population reg-
istries network. Information concerning the cause of death
was not available. Follow-up was calculated from the date
of diagnosis to the date of death from any cause, or until 31
December 2011.
Statistical Analysis
Statistical analyses were performed using SPSS software
version 20.0 (IBM Corporation, Armonk, NY, USA).
Baseline characteristics were analyzed using the v2 test, or,
in case of an expected cell count\5, the Fishers exact test
or Monte Carlo simulation (number of samples 10,000)
was used. OS was analyzed using Kaplan–Meier curves,
and the log-rank test was used to compare survival curves.
Patients who were alive at the end of follow-up were
censored. Independent predictor variables for survival were
estimated using Cox regression, and binary logistic
regression was used to analyze predictors for pathologic
response. Hazard ratios (HRs) resulting from Cox regres-
sion and odds ratios (ORs) resulting from logistic
regression were reported alongside a 95 % confidence
interval (CI). Variables to be taken into account in multi-
variable analyses were selected by significance during
univariable analysis and clinical relevance; however, the
variables of CRM and distance to anus were not included in
the multivariable models because data were missing for
patients before 2008. Reference groups for multivariable
analyses were chosen based on the largest group size and
results are only given in case of a p value of \0.1. Sta-
tistical significance was defined as p\ 0.05.
RESULTS
The median interval between CRT and surgery was
8 weeks for ET and LARC patients. Baseline characteris-
tics of patients included in the cohort were comparable
with those of patients who were excluded because of
unknown treatment interval and intermediate tumor stage
(data not shown). Median follow-up was 50 months (range
5–106) in ET patients and 50 months (range 5–109) in
LARC patients.
In ET patients, baseline characteristics were similar for
groups divided according to treatment interval (Table 1),
while in LARC patients, treatment intervals were longer for
cT4 tumors (p = 0.007) and clinical node-positive tumors
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Mean (range) 63 (45–79) 63 (34–85) 63 (36–84) 65 (39–84) 68 (62–76)
\45 – 5 (6.0) 3 (4.1) 1 (3.2) –
45–59 8 (34.8) 19 (22.6) 24 (32.4) 5 (16.1) –
60–74 11 (47.8) 45 (53.6) 39 (52.7) 18 (58.1) 4 (80.0)
[75 4 (17.4) 15 (17.9) 8 (10.8) 7 (22.6) 1 (20.0)
Sex 0.549
Male 17 (73.9) 54 (64.3) 42 (56.8) 17 (54.8) 3 (60.0)
Female 6 (26.1) 30 (35.7) 32 (43.2) 14 (45.2) 2 (40.0)
Distance to anus, cm
(n = 189)a
0.284
0–5 6 (42.9) 48 (64.0) 44 (67.6) 22 (73.3) 3 (60.0)
6–10 7 (50.0) 20 (26.7) 10 (15.4) 5 (16.7) 2 (40.0)
[10 1 (7.1) 5 (6.7) 5 (7.7) 1 (3.3) –
Unknown – 2 (2.7) 6 (9.2) 2 (6.7) –
Histology 1.000
AC 21 (91.3) 77 (91.7) 68 (91.9) 29 (93.5) 5 (100.0)
MC 2 (8.7) 6 (7.1) 6 (8.1) 2 (6.5) –
SRCC – 1 (1.2) – – –
cT stage 0.927
cT1 – – – – –
cT2 3 (13.0) 13 (15.5) 13 (17.6) 6 (19.4) –
cT3 20 (87.0) 71 (84.5) 61 (82.4) 25 (80.6) 5 (100.0)
Surgical procedure 0.393
LAR 6 (26.1) 30 (35.7) 26 (35.1) 10 (32.3) 3 (60.0)
APR 16 (69.6) 45 (53.6) 40 (54.1) 14 (45.2) 1 (20.0)
Hartmann 1 (4.3) 5 (6.0) 3 (4.1) 2 (6.5) 1 (20.0)
Other – 4 (4.8) 5 (6.8) 5 (16.1) –
ypT stage 0.342
ypT0 8 (34.8) 12 (14.3) 18 (24.3) 4 (12.9) 2 (40.0)
ypT1 2 (8.7) 8 (9.5) 6 (8.1) 6 (19.4) –
ypT2 4 (17.4) 29 (34.5) 18 (24.3) 11 (35.5) –
ypT3 9 (39.1) 33 (39.3) 28 (37.8) 10 (32.3) 3 (60.0)
ypT4 – – – – –
ypTx – 2 (2.4) 4 (5.4) – –
ypN stage 0.171
ypN0 19 (82.6) 70 (83.3) 55 (74.3) 23 (74.2) 3 (60.0)
ypN1 3 (13.0) 8 (9.5) 6 (8.1) 5 (16.1) 2 (40.0)
ypN2 1 (4.3) 4 (4.8) 4 (5.4) – –
ypNx – 2 (2.4) 9 (12.2) 3 (9.7) –
Differentiation 0.203
Well – – – 2 (6.5) –
Intermediate 3 (13.0) 22 (26.2) 18 (24.3) 6 (19.4) 3 (60.0)
Poor – 5 (6.0) 3 (4.1) 2 (6.5) –
Unknown 20 (87.0) 57 (67.9) 53 (71.6) 21 (67.7) 2 (40.0)
Data are expressed as n (%) unless otherwise specified
AC adenocarcinoma not otherwise specified, MC mucinous adenocarcinoma, SRCC signet ring cell adenocarcinoma, LAR low anterior resection,
APR abdominoperineal resection, ET early tumor, CRT chemoradiation therapy
a Data were only available from 2008 and beyond
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Mean (range) 64 (31–82) 63 (32–85) 64 (27–83) 64 (39–82) 65 (42–83)
\45 4 (4.0) 24 (6.5) 21 (5.5) 3 (1.9) 1 (1.4)
45–59 30 (29.7) 100 (27.1) 115 (30.3) 47 (30.5) 17 (24.6)
60–74 56 (55.4) 203 (55.0) 206 (54.2) 87 (56.5) 41 (59.4)
[75 11 (10.9) 42 (11.4) 38 (10.0) 17 (11.0) 10 (14.5)
Sex 0.907
Male 63 (62.4) 224 (60.7) 240 (63.2) 97 (63.0) 40 (58.0)
Female 38 (37.6) 145 (39.3) 140 (36.8) 57 (37.0) 29 (42.0)
Distance to anus, cm
(n = 926)a
0.052
0–5 24 (42.1) 145 (46.6) 173 (48.7) 76 (54.3) 32 (50.8)
6–10 19 (33.3) 125 (40.2) 130 (36.6) 37 (26.4) 25 (39.7)
[10 8 (14.0) 24 (7.7) 37 (10.4) 14 (10.0) 1 (1.6)
Unknown 6 (10.5) 17 (5.5) 15 (4.2) 13 (9.3) 5 (7.9)
Histology 0.448
AC 96 (95.0) 335 (90.8) 341 (89.7) 134 (87.0) 63 (91.3)
MC 5 (5.0) 33 (8.9) 37 (9.7) 19 (12.3) 5 (7.2)
SRCC – 1 (0.3) 2 (0.5) 1 (0.6) 1 (1.4)
cT-stage 0.007
cT3 78 (77.2) 292 (79.1) 285 (75.0) 113 (73.4) 40 (58.0)
cT4 23 (22.8) 77 (20.9) 95 (25.0) 41 (26.6) 29 (42.0)
cN-stage 0.019
cN0 4 (4.0) 18 (4.9) 24 (6.3) 5 (3.2) 7 (10.1)
cN1 64 (63.4) 193 (52.3) 171 (45.0) 67 (43.5) 35 (50.7)
cN2 22 (21.8) 111 (30.1) 145 (38.2) 61 (39.6) 18 (26.1)
cNx 11 (10.9) 47 (12.7) 40 (10.5) 21 (13.6) 9 (13.0)
Surgical procedure 0.032
LAR 42 (41.6) 176 (47.7) 170 (44.7) 55 (35.7) 27 (39.1)
APR 49 (48.5) 150 (40.7) 150 (39.5) 61 (39.6) 29 (42.0)
Hartmann 5 (5.0) 23 (6.2) 25 (6.6) 20 (13.0) 7 (10.1)
Other 5 (5.0) 20 (5.4) 35 (9.2) 18 (11.7) 6 (8.7)
ypT stage 0.003
ypT0 8 (7.9) 52 (14.1) 78 (20.5) 35 (22.7) 13 (18.8)
ypT1 5 (5.0) 16 (4.3) 23 (6.1) 12 (7.8) 2 (2.9)
ypT2 23 (22.8) 103 (27.9) 79 (20.8) 28 (18.2) 13 (18.8)
ypT3 57 (56.4) 171 (46.3) 166 (43.7) 62 (40.3) 27 (39.1)
ypT4 7 (6.9) 17 (4.6) 22 (5.8) 14 (9.1) 11 (15.9)
ypTx 1 (1.0) 10 (2.7) 12 (3.2) 3 (1.9) 2 (4.3)
ypN stage 0.565
ypN0 64 (63.4) 237 (64.2) 244 (64.2) 101 (65.6) 45 (65.2)
ypN1 25 (24.8) 80 (21.7) 81 (21.3) 33 (21.4) 14 (20.3)
ypN2 12 (11.9) 51 (13.8) 49 (12.9) 19 (12.3) 7 (10.1)
ypNx – 1 (0.3) 6 (1.6) 1 (0.6) 3 (4.3)
Differentiation 0.221
Well 2 (2.0) 5 (1.4) 5 (1.3) – 3 (4.3)
Intermediate 27 (26.7) 83 (22.5) 79 (20.8) 38 (24.7) 20 (29.0)
Poor 4 (4.0) 17 (4.6) 25 (6.6) 13 (8.4) 5 (7.2)
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(p = 0.019; Table 2). The type of performed surgical
procedure also differed between groups (p = 0.032);
patients in the longer treatment interval groups more often
underwent Hartmann procedures (Table 2).
Early Tumors
The overall pCR rate in ET patients was 16.1 %. The
highest pCR rates and good response rates in ET patients
were demonstrated after a treatment interval of 5–6 weeks
(30.4 %, n = 7; and 39.1 %, n = 9, respectively; Fig. 1a),
which was not significantly different in either univariable
or multivariable logistic regression analysis (pCR,
p = 0.148 [Electronic Supplementary Table S1]; good
response, p = 0.541).
No relation was found between treatment interval and
CRM involvement (Fig. 1a), ypT stage, or ypN stage
(Table 1). Differences in treatment interval did not affect
survival during either univariable or multivariable analysis
(Electronic Supplementary Table S2). The relationship












5-6 weeks 7-8 weeks 9-10 weeks 11-12 weeks 13-14 weeks
Pathologic response 23 84 74 31 5
CRM 11 69 60 22 4
Early tumors



















5-6 weeks 7-8 weeks 9-10 weeks 11-12 weeks 13-14 weeks
Pathologic response 101 369 380 154 69
CRM 56 257 409 123 46
LARC








FIG. 1 Percentage of patients
with a pCR or good response,
and percentage of patients with
a positive CRM. a Patients with
early tumors, b LARC patients.
The tables show the number of
patients in each group. For
CRM, data were only available


















Unknown 68 (67.3) 264 (71.5) 271 (71.3) 103 (66.9) 41 (59.4)
Data are expressed as n (%) unless otherwise specified
AC adenocarcinoma not otherwise specified, MC mucinous adenocarcinoma, SRCC signet ring cell adenocarcinoma, LAR low anterior resection,
APR abdominoperineal resection, LARC locally advanced rectal cancer, CRT chemoradiation therapy
a Data were only available from the year 2008 and beyond
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between pathologic response and OS was also analyzed,
and patients with a complete or good pathologic response
did not show an improved OS compared with other ET
patients. In patients with a pCR, 5-year OS was 82.9 %
(95 % CI 75.8–90.0) versus 75.6 % (95 % CI 71.6–79.6) in
non-pCR patients (p = 0.332).
Locally Advanced Rectal Cancer
The overall pCR rate in LARC patients was 15.9 %.
pCR and good response rates were highest after an 11–
12 week interval, with rates of 20.8 % (p = 0.028) and
26.6 % (p = 0.013), respectively (Fig. 1b). Outcomes of
logistic regression are depicted in Table 3 and show that
there was a higher odds of pCR in the 9- to 10-week and
11- to 12-week treatment interval groups than in the 7- to
8-week treatment interval group. This was also the case for
good response rates (9–10 weeks: OR 1.67, 95 % CI 1.14–
2.45, p = 0.008; and 11–12 weeks: OR 2.15, 95 % CI
1.34–3.48, p = 0.002). Other predictors for pCR in LARC
patients were age, histology, and tumor differentiation
(Table 3). Patients who were 45–59 years of age had lower
pCR rates compared with patients who were aged between
60 and 74 years (OR 0.58, 95 % CI 0.38–0.88), and
mucinous tumors were associated with lower pCR rates
compared with patients with AC tumors (OR 0.19, 95 % CI
0.07–0.52; Table 3). pCR was more common in patients
with an unknown tumor differentiation compared with
patients with an intermediate tumor differentiation (OR
1.95, 95 % CI 1.25–3.05).
The treatment interval in LARC patients was related to
CRM involvement during univariable analysis (Fig. 1b),
with the lowest rate of CRM-positive resections after a
treatment interval of 7–8 weeks. Treatment interval did not
affect ypN stage (p = 0.565). ypT0 was most prevalent in
the 9- to 10-week (20.5 %) and 11- to 12-week (22.7 %)
groups (p = 0.003). Longer treatment intervals did not
affect survival (p = 0273; Table 4). Variables that did
affect OS in LARC patients on multivariable analysis were
TABLE 3 Outcomes of multivariable logistic regression analysis of
variables predicting pCR in LARC patients
Odds ratio (95 % CI) Adjusted p value
Treatment interval, weeks 0.022
5–6 0.57 (0.25–1.28) 0.172
7–8 1.00 –
9–10 1.56 (1.03–2.37) 0.037
11–12 1.94 (1.15–3.26) 0.013
13–14 1.44 (0.68–3.04) 0.346
Age, years 0.006
\45 1.78 (0.90–3.51) 0.099
45–59 0.58 (0.38–0.88) 0.011
60–74 1.00 –
[75 0.63 (0.35–1.15) 0.132
Histology 0.006
AC 1.00 –
MC 0.19 (0.07–0.52) 0.001
SRCC 1.19 (0.10–13.60) 0.887
Differentiation 0.014
Well 0.59 (0.07–4.76) 0.620
Intermediate 1.00 –
Poor 1.01 (0.36–2.80) 0.989
Unknown 1.95 (1.25–3.05) 0.003
Other variables entered into the model were sex, cT stage, cN stage,
and year of surgery
AC adenocarcinoma not otherwise specified, MC mucinous adeno-
carcinoma, SRCC signet ring cell adenocarcinoma, pCR pathologic
complete response, LARC locally advanced rectal cancer, CI confi-
dence interval
TABLE 4 Multivariable Cox regression analysis of variables pre-
dicting overall survival in LARC patients
Hazard ratio (95 % CI) Adjusted p-value
Treatment interval, weeks 0.273
5–6 1.39 (0.95–2.03) 0.095
7–8 1.00 –
9–10 0.99 (0.73–1.34) 0.935
11–12 1.13 (0.77–1.66) 0.543








\45 0.67 (0.34–1.34) 0.259
45–59 0.91 (0.68–1.23) 0.548
60–74 1.00 –
[75 2.01 (1.44–2.80) \0.000
Histology 0.093
AC 1.00 –
MC 1.28 (0.88–1.84) 0.197
SRCC 3.36 (0.96–11.79) 0.058
Differentiation \0.000
Well 0.63 (0.20–2.03) 0.443
Intermediate 1.00 –
Poor 2.43 (1.56–3.80) \0.000
Unknown 0.94 (0.70–1.26) 0.675
pCR pathologic complete response (ypT0N0), AC adenocarcinoma
not otherwise specified, MC mucinous adenocarcinoma, SRCC signet
ring cell adenocarcinoma, LARC locally advanced rectal cancer, CI
confidence interval
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pathologic response, age, sex and differentiation. LARC
patients with a pCR had a better OS than patients who did
not have a pCR: 88.9 % (95 % CI 86.3–91.5) of patients
with pCR were alive after 5 years of follow-up compared
with 71.0 % (95 % CI 69.3–72.7) of patients without pCR
(HR 0.43, 95 % CI 0.27–0.68). Patients who were 75 years
of age or older were associated with poorer survival
compared with patients who were aged between 60 and
74 years (HR 2.0.1, 95 % CI 1.44–2.80). Patients who had
a poorly differentiated tumor were associated with a poorer
survival compared with patients whose tumor was inter-
mediately differentiated (HR 2.43, 95 % CI 1.56–3.80).
Female patients had better OS compared with male patients
(HR 0.74, 95 % CI 0.57–0.96).
DISCUSSION
Neoadjuvant CRT has been widely implemented in the
treatment of rectal cancer to enable downsizing and
downstaging and to improve outcome. In the present
nationwide study, a treatment interval of 9–12 weeks led to
the highest rates of pCR in LARC patients. This is a longer
treatment interval than the usually reported interval in the
literature, and half of the LARC patients in our cohort were
operated within this 4-week interval. In ET patients,
treatment interval did not seem to influence pCR rates. The
length of treatment interval did not affect OS in either
LARC or ET patients.
In addition to various important factors such as tumor
stage, histology, and CRM,20 tumor response has been
recognized as an important predictor of local recurrence and
OS in rectal cancer surgery.21 It has repeatedly been sug-
gested that the length of treatment interval between
neoadjuvant therapy and surgery might influence pathologic
response.22–26 To date, only two randomized controlled
trials have been published comparing short and long treat-
ment intervals between neoadjuvant therapy and surgery,
and the outcomes are contradictory. The Lyon R90-01 trial
(N = 201) in 1999 showed better pathologic tumor down-
staging (T0–1) in a long interval group (6–8 weeks; 26 %)
compared with a short interval group (2 weeks; 10.3 %;
p = 0.005) between radiotherapy and surgery.27 In 2014,
Saglam et al. compared outcomes for 4 or 8 weeks post-
CRT (N = 153) and could not identify differences in
complete response levels.28 A recent meta-analysis of all
non-randomized trials on this topic (N = 3584) showed
increased pCR rates after an interval of more than 6–8
weeks compared with pCR rates after a shorter treatment
interval (from 13.7 to 19.5 %).24 This corroborates well
with the findings in the current cohort of LARC patients.
Other factors that were identified as predictors of
pathologic response in LARC patients were age, tumor
differentiation, and mucinous histology. The latter is in
accordance with a recent study from our group that
reported on outcomes in LARC patients with mucinous AC
and AC. This study demonstrated that pCR was not
observed in any mucinous AC patient compared with over
16 % in AC patients, which did not affect survival.29 In the
current cohort, pCR rates were again significantly lower in
mucinous AC patients without an effect on OS. A recent
study of the National Cancer Data Base (NCDB)
(N = 23,747) identified a longer treatment interval, lower
tumor grade, lower cT and cN stage, and higher radiation
dose as predictors for pCR.26 Other studies did not identify
any independent determinants in achieving pCR other than
treatment interval.22,23
Outcomes for ET patients were analyzed separately in
the current study and the treatment interval in these
patients was not related to pathologic response. As far as
we know, no other study to date has analyzed the effects of
treatment interval in a select group of ET patients. The
observed overall pCR rate in ET patients in the current
study was 16.1 %, which is substantially lower than
reported pCR rates in recent literature of 22–44 %.6,8,9,11,30
Several issues for this discrepancy can be noted. First, most
of these studies with higher pCR rates are conducted
prospectively and patient selection might explain the high
response rates. Furthermore, in the present study, details on
clinical staging could not be checked, and stages could
have been higher. Also, the group of ET patients is prob-
ably biased since these patients received CRT, although
this is not generally recommended according to national
guidelines. Larger studies are needed to assess whether the
duration of treatment interval influences pathologic
response in ET patients and could reduce the need for
surgery.
Treatment interval was not related to OS in either ET or
LARC patients. Only a limited number of studies have
demonstrated improved survival for LARC patients with a
long treatment interval.15,31 To the best of our knowledge,
none of the studies to date that have analyzed the rela-
tionship between a prolonged treatment interval and OS
have specifically looked into outcomes of ET
patients.15,25,28,31–33
The present study describes a population-based analysis
of a large number of rectal cancer patients, however it has
some limitations. The retrospective nature of this study
poses particular caution because of heterogeneity in CRT
regimens and other potential confounding variables. For
example, reasons for either a short or longer treatment
interval could not be retrieved. It is not inconceivable that
patient or tumor characteristics have influenced the timing
of surgery. In addition, 1186 patients had to be excluded
from analysis because the length of their treatment interval
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was unknown. This could have introduced a selection bias,
but comparison of this group with the included patients in
the study did not show differences in characteristics.
Randomized trials are necessary to determine the optimal
treatment interval following CRT. Several trials are
ongoing at the moment and are evaluating treatment
intervals of 6–7 weeks versus 11–12 weeks following
neoadjuvant CRT.34–36
Promising outcomes have been reported in studies ana-
lysing different treatment modalities, including a wait and
see approach12,14 and local transanal excision.5–11 Onco-
logical outcomes have been shown to be comparable with
those of patients with a pCR after major surgery.5,6,11,12,14
Moreover, a reduction in the number of complications and
permanent stomas might lead to a better functional out-
come;12 however, these outcomes still have to be
confirmed in randomized trials. Another drawback of the
rectum-saving approach is that patients who need com-
pletion surgery will be overtreated with CRT, which has
potential and serious side effects and long-term complica-
tions.7,14 It is therefore necessary that selection criteria of
eligible patients be further explored prior to
implementation.
CONCLUSIONS
Treatment intervals of 9–12 weeks seem to improve the
chances of pCR in LARC patients, without an effect on OS.
The optimal treatment interval between surgery and CRT
for ET patients could not be identified. The ongoing search
for minimally invasive surgery drives the need for explo-
ration of factors that improve pathologic response.
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